350 / 412
The
American Journal
of
GASTROENTEROLOGY
7. Grudell AB, Alexander JA, Enders FB
et al.
Validation of the Mayo
Dysphagia Questionnaire. Dis Esophagus 2007;20:202–5.
8. Johnson LF, Demeester TR. Twenty-four-hour pH monitoring of the distal
esophagus. A quantitative measure of gastroesophageal reflux. Am J
Gastroenterol 1974;62:325–32.
9. Johnson LF, DeMeester TR. Development of the 24-hour intraesophageal
pH monitoring composite scoring system. J Clin Gastroenterol 1986;8
(Suppl 1): 52–8.
10. Noel RJ, Putnam PE, Collins MH
et al.
Clinical and immunopathologic
effects of swallowed fluticasone for eosinophilic esophagitis. Clin Gastro-
enterol Hepatol 2004;2:568–75.
11. Konikoff MR, Noel RJ, Blanchard C
et al.
A randomized, double-blind,
placebo-controlled trial of fluticasone propionate for pediatric eosinophilic
esophagitis. Gastroenterology 2006;131:1381–91.
12. Schaefer ET, Fitzgerald JF, Molleston JP
et al.
Comparison of oral
prednisone and topical fluticasone in the treatment of eosinophilic
esophagitis: a randomized trial in children. Clin Gastroenterol Hepatol
2008;6:165–73.
13. Peterson KA, Thomas KL, Hilden K
et al.
Comparison of esomeprazole to
aerosolized, swallowed fluticasone for eosinophilic esophagitis. Dig Dis Sci
2010;55:1313–9.
14. Alexander JA, Jung KW , Arora AS
et al.
Swallowed fluticasone improves
histologic but not symptomatic response of adults with eosinophilic eso-
phagitis. Clin Gastroenterol Hepatol 2012;10:742–9.
15. Sperry SL, Shaheen NJ, Dellon ES. Toward uniformity in the
diagnosis of eosinophilic esophagitis (EoE): the effect of guidelines
on variability of diagnostic criteria for EoE. Am J Gastroenterol 2011;
106:824–32.
16. Straumann A, Conus S, Degen L
et al.
Budesonide is effective in adolescent
and adult patients with active eosinophilic esophagitis. Gastroenterology
2010;139:1526–37.
17. Straumann A, Conus S, Degen L
et al.
Long-term budesonide maintenance
treatment is partially effective for patients with eosinophilic esophagitis.
Clin Gastroenterol Hepatol 2011;9:400–9.
18. Aceves SS, Bastian JF, Newbury RO
et al.
Oral viscous budesonide: a poten-
tial new therapy for eosinophilic esophagitis in children. Am J Gastroen-
terol 2007;102:2271–9.
19. Dellon ES, Sheikh A, Speck O
et al.
Viscous Topical Is More Effective Than
Nebulized Steroid Therapy for Patients With Eosinophilic Esophagitis.
Gastroenterology 2012;143:321–4.
20. Spechler SJ, Genta RM, Souza RF. Thoughts on the complex relationship
between gastroesophageal reflux disease and eosinophilic esophagitis.
Am J Gastroenterol 2007;102:1301–6.
21. Cortes JR, Rivas MD, Molina-Infante J
et al.
Omeprazole inhibits IL-4 and
IL-13 signaling signal transducer and activator of transcription 6 activation
and reduces lung inflammation in murine asthma. J Allergy Clin Immunol
2009;124:607–10.
22. Zhang X CE, Hou X
et al.
In esophageal epithelial cell lines from patients
with eosinophilic esophagitis (EoE), omeprazole blocks the stimulated
secretion of eotaxin-3: a potential anti-inflammatory effect of omeprazole
in EoE that is independent of acid inhibition. Gastroenterology 2010;138
(suppl 1): S–122.
23. Dranove JE, Horn DS, Davis MA
et al.
Predictors of response to proton
pump inhibitor therapy among children with significant esophageal eosi-
nophilia. J Pediatr 2009;154:96–100.
24. Molina-Infante J, Ferrando-Lamana L, Ripoll C
et al.
Esophageal eosi-
nophilic infiltration responds to proton pump inhibition in most adults.
Clin Gastroenterol Hepatol 2011;9:110–7.
25. Pentiuk S, Putnam PE, Collins MH
et al.
Dissociation between symptoms
and histological severity in pediatric eosinophilic esophagitis. J Pediatr
Gastroenterol Nutr 2009;48:152–60.
26. Schoepfer AM, Gonsalves N, Bussmann C
et al.
Esophageal dilation in
eosinophilic esophagitis: effectiveness, safety, and impact on the underlying
inflammation. Am J Gastroenterol 2010;105:1062–70.
27. Straumann A, Spichtin HP , Grize L
et al.
Natural history of primary eosi-
nophilic esophagitis: a follow-up of 30 adult patients for up to 11.5 years.
Gastroenterology 2003;125:1660–9.
drafting of the manuscript, critical revision of the manuscript for
important intellectual content: Fouad J. Moawad; study concept and
design, study enrollment, acquisition of data, analysis and inter-
pretation of data, drafting of the manuscript, critical revision of the
manuscript for important intellectual content: Ganesh R. Veerappan;
data collection, verification and analysis, drafting of the manuscript:
Johnny A. Dias; histological analysis, drafting of the manuscript:
Thomas P. Baker; study concept and design, analysis and interpreta-
tion of data, drafting of the manuscript, critical revision of the
manuscript for important intellectual content: Corinne L.
Maydonovitch; study concept and design, drafting of the manuscript,
critical revision of the manuscript for important intellectual
content: Roy K.H. Wong.
Financial support:
None.
Potential competing interests
: None.
Disclaimer
The opinions are solely those of the authors and do not represent an
endorsement by the Department of Defense. This is US Government
work. There are no restrictions on its use.
Study Highlights
WHAT IS CURRENT KNOWLEDGE
3
Topical steroids are commonly used as first line treatment
for patients with a clinical presentation suggestive of EoE
and who have dense eosinophilic infiltration.
3
PPI therapy is often prescribed in esophageal eosinophilia
patients to help treat coexisting GERD and establish
diagnosis of EoE.
WHAT IS NEW HERE
3
Topical fluticasone had a lower than expected response rate
which may be dose and delivery related.
3
PPIs induce histological response in some patients with eso-
phageal eosinophilia regardless of the presence of GERD.
3
PPIs significantly improved clinical symptoms in patients
with esophageal eosinophilia even in the absence of GERD.
REFERENCES
1. Moawad FJ, Veerappan GR, Wong RK. Eosinophilic esophagitis. Dig Dis
Sci 2009;54:1818–28.
2. Liacouras CA, Furuta GT, Hirano I
et al.
Eosinophilic esophagitis:
updated consensus recommendations for children and adults. J Allergy
Clin Immunol 2011;128:3–20.
3. Furuta GT, Liacouras CA, Collins MH
et al.
Eosinophilic esophagitis in
children and adults: a systematic review and consensus recommendations
for diagnosis and treatment. Gastroenterology 2007;133:1342–63.
4. Ngo P , Furuta GT, Antonioli DA
et al.
Eosinophils in the esophagus-
peptic or allergic eosinophilic esophagitis? Case series of three patients
with esophageal eosinophilia. Am J Gastroenterol 2006;101:1666–70.
5. Desai TK, Stecevic V , Chang CH
et al.
Association of eosinophilic inflammation
with esophageal food impaction in adults. Gastrointest Endosc 2005;61:795–801.
6. Hirano I. Eosinophilic esophagitis and gastroesophageal reflux disease:
there and back again. Clin Gastroenterol Hepatol 2011;9:99–101.
125